The global biologics market was valued at USD 495 billion in 2025. The market is projected to grow from USD 540 billion in 2026 to USD 1051 billion by 2034, exhibiting a compound annual growth rate of 8.68% during the forecast period. Contrive Datum Insights presents this information in its report titled "Biologics Market Size, Share & Industry Analysis, By Application (Oncology, Autoimmune & Inflammatory Diseases, Infectious Diseases, Cardiovascular Diseases, Others), Product (Biochemical Analysis, Diagnostic Imaging, Direct MAB Agents, Targeting MAB Agents, Murine, Chimeric, Humanized, Human, Protein Purification, Recombinant Proteins, Antisense, RNAi, & Molecular Therapy, Others), Disease category (MABs, Antisense, RNAi, & Molecular Therapy, Recombinant Proteins, Cardiovascular Disorders, Hematological Disorders, Others), Biologics manufacturing (Outsourced, In-house), End user (Pharmaceutical & Biotechnology Companies, Contract Research & Manufacturing Organizations, Academic & Research Institutes, Others), and Regional Forecast, 2026-2034".
Biologics are medicines manufactured from living cells, not synthesized chemically, and include monoclonal antibodies, recombinant proteins, and nucleic acid-based therapies such as antisense and RNAi constructs, together with the diagnostic reagents and imaging agents built on the same biological platforms. They are produced as injectable or infused products administered in hospital, specialty-pharmacy, or infusion-center settings, and used both to treat chronic and acute disease and to support diagnostic testing. Buyers include the pharmaceutical and biotechnology manufacturers that develop and commercialize these products, the contract manufacturers that produce them under agreement, and the academic and research institutions that use them in study and testing.
Expansion of monoclonal antibody approvals across oncology and immunology
Expansion of monoclonal antibody approvals across oncology and immunology is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 8.68% a year, the application lines exposed to it move fastest: Others compounds at 10.1%, taking its share of revenue from 8% to 9% and its value from USD 39.6 billion to USD 94.6 billion.
The study also runs a bull case: the bull case assumes biosimilar entry stays slower than currently scheduled and at least one additional antibody-drug conjugate or bispecific format wins approval earlier than expected, keeping originator pricing power intact for longer. That path ends 2034 at USD 1145.6 billion, above the USD 1051 billion base case.
Against that, the bear case assumes an accelerated wave of biosimilar approvals compresses pricing faster than planned and a manufacturing capacity delay pushes several new product launches into later years. On that reading 2034 revenue stops at USD 956.4 billion. The weight of the problem sits in Autoimmune & Inflammatory Diseases: 28% of 2025 revenue growing at 7.79%, well under the market's 8.68%.
Oncology Scale Against Others Momentum
Competition in the global biologics market runs along the application axis, not the regional one. Oncology holds 38% of 2025 revenue at USD 188.1 billion and remains the largest line through 2034 at 42%, making it the position hardest for a challenger to take. Others, growing at 10.1%, is where share actually changes hands. A supplier established in one is not thereby established in the other, so a field of this size persists in a market of USD 495 billion.
What Else the Report Shows
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Product | Targeting MAB Agents | 16% · USD 79.2 billion | Antisense, RNAi, & Molecular Therapy 19.8% |
| Disease category | MABs | 30% · USD 148.5 billion | Antisense, RNAi, & Molecular Therapy 15.6% |
| Biologics manufacturing | In-house | 58% · USD 287.1 billion | Outsourced 11.7% |
| End user | Pharmaceutical & Biotechnology Companies | 62% · USD 306.9 billion | Contract Research & Manufacturing Organizations 12.4% |
- Regionally, the lead sits with North America: 42% of 2025 global revenue, USD 207.9 billion rising to USD 399.4 billion in 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 22.5% in 2025 to 27% in 2034, with revenue growing from USD 111.4 billion to USD 283.8 billion.
- At 4.2% of 2025 revenue and 5.5% by 2034, Middle East and Africa is the smallest region throughout.
- Oncology was the leading application line in 2025, taking 38% of revenue at USD 188.1 billion.
- Others is projected to grow at 10.1% over the forecast period, the fastest of any application line.
- The United States is the largest single country market at USD 176.7 billion in 2025, 35.7% of global revenue.
The report segments the market across five axes; by application, and by product, disease category, biologics manufacturing and end user; with revenue and a growth rate for every line in every year from 2020 to 2034, alongside bear, base and bull scenarios for the headline total at USD 956.4 billion and USD 1145.6 billion by 2034. It covers all five regions with country-level breakdowns, the competitive landscape, and the research methodology behind every estimate. Delivered as a PDF; a free sample is available on request.